Synapse - Taha Merghoub

Results (17)

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

Journal Article

Memon, D.; Schoenfeld, A. J.; Ye, D.; Fromm, G.; Rizvi, H.; Zhang, X.; Keddar, M. R.; Mathew, D.; Yoo, K. J.; Qiu, J.; more...
Cancer Cell (2024)

Fulltext@MSK | Save

Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer

Journal Article

Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
Clinical Cancer Research (2023)

Fulltext@MSK | Save

Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade

Journal Article

Pai, J. A.; Hellmann, M. D.; Sauter, J. L.; Mattar, M.; Rizvi, H.; Woo, H. J.; Shah, N.; Nguyen, E. M.; Uddin, F. Z.; Quintanal-Villalonga, A.; more...
Cancer Cell (2023)

Fulltext@MSK | Save

Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC)

Meeting Abstract

Harding, J. J.; Yarmohammadi, H.; Reiss, K. A.; Chou, J. F.; Capanu, M.; Do, R. K. G.; Khalil, D.; El Dika, I. H.; Ferrer, C. S.; Heffernan, O.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer

Meeting Abstract

Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Immunotherapy-mediated thyroid dysfunction: Genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer

Journal Article

Luo, J.; Martucci, V. L.; Quandt, Z.; Groha, S.; Murray, M. H.; Lovly, C. M.; Rizvi, H.; Egger, J. V.; Plodkowski, A. J.; Abu-Akeel, M.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)

Meeting Abstract

Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
Blood (2020)

Fulltext@MSK | Save

Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis

Meeting Abstract

Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition

Journal Article

Nabet, B. Y.; Esfahani, M. S.; Moding, E. J.; Hamilton, E. G.; Chabon, J. J.; Rizvi, H.; Steen, C. B.; Chaudhuri, A. A.; Liu, C. L.; Hui, A. B.; more...
Cell (2020)

Fulltext@MSK | Save

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC

Journal Article

Hellmann, M. D.; Nabet, B. Y.; Rizvi, H.; Chaudhuri, A. A.; Wells, D. K.; Dunphy, M. P. S.; Chabon, J. J.; Liu, C. L.; Hui, A. B.; Arbour, K. C.; more...
Clinical Cancer Research (2020)

Fulltext@MSK | Save